Delving into the Latest Updates on Huili Pharmaceutical (Suzhou) Co., Ltd. with Synapse

Overview

Tags

Other Diseases

Small molecule drug

Disease domain score

A glimpse into the focused therapeutic areas

No Data

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

No Data

Top 5 Drug Type	Count

Small molecule drug	1

Primary study objective: To evaluate the safety and tolerability of a single dose of HL008 for injection in Chinese patients with schizophrenia; Secondary study objective: To evaluate the pharmacokinetic (PK) characteristics of a single dose of HL008 for injection in Chinese patients with schizophrenia.

Start Date-

Sponsor / Collaborator

Bosikon (Hangzhou) Biomedical Co., Ltd.

[+1]

100 Clinical Results associated with Huili Pharmaceutical (Suzhou) Co., Ltd.

Login to view more data

0 Patents (Medical) associated with Huili Pharmaceutical (Suzhou) Co., Ltd.

Login to view more data

100 Deals associated with Huili Pharmaceutical (Suzhou) Co., Ltd.

Login to view more data

100 Translational Medicine associated with Huili Pharmaceutical (Suzhou) Co., Ltd.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 23 Feb 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Phase 1 Clinical

1

Login to view more data